Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Evaluated in…
NIAID has initiated a Phase 3 clinical trial to evaluate the efficacy and safety of hyperimmune globulin products, including Emergent’s COVID-19 Human Immune Globulin (COVID-HIG), for potential treatment of COVID-19 in adult patients at…